Introduction
============

Since revascularization of the left anterior descending artery ( LAD) was first introduced in the 1960s \[[@b1-kjtcv-51-008]\], the applications of coronary artery bypass grafting (CABG) in coronary artery disease have expanded to include minimally invasive direct coronary artery bypass grafting (MIDCAB). MIDCAB has 2 major advantages over other treatment interventions: one is the use of a small incision through a left anterolateral thoracotomy without cardiopulmonary bypass, and the other is the fact that it is the best option for grafting the left internal thoracic artery (LITA) to the LAD \[[@b2-kjtcv-51-008],[@b3-kjtcv-51-008]\]. Those advantages result in better outcomes, with fewer complications in terms of stroke, mediastinitis, and bleeding, as well as lower medical costs \[[@b2-kjtcv-51-008],[@b4-kjtcv-51-008]\]. Recently, LITA-to-LAD MIDCAB has been considered to be the treatment of choice in single-vessel disease in the proximal LAD \[[@b5-kjtcv-51-008]\].

However, there are some obstacles hindering the universal use of MIDCAB in specific clinical situations. The fact that thoracotomy is more painful than sternotomy and the need for a learning curve, causing a longer operative time and target vessel misidentification, may be potential pitfalls of MIDCAB \[[@b6-kjtcv-51-008],[@b7-kjtcv-51-008]\]. In this study, we evaluate the recent MIDCAB results from a single center and discuss the implications of our findings for this approach.

Methods
=======

1) Patients
-----------

Between August 2007 and July 2015, a total of 66 patients underwent a MIDCAB operation through a left anterior minithoracotomy at Seoul National University Bundang Hospital, and the procedures were carried out by 3 cardiac surgeons who shared the same operative technique and strategy for MIDCAB. Preoperative, intraoperative, postoperative, and follow-up data were collected, including major adverse cardiovascular and cerebrovascular events (MACCE), graft patency, and the need for re-intervention. The preoperative clinical variables and demographics of the patients undergoing MIDCAB are summarized in [Table 1](#t1-kjtcv-51-008){ref-type="table"}.

The institutional review board of Seoul National University Bundang Hospital approved the present study (B-1511/322-109). And the requirement for informed patient consent was waived due to the retrospective nature of the study.

2) Indications
--------------

We considered MIDCAB in the following circumstances: (1) definitive MIDCAB, for single-vessel disease of the proximal LAD, including restenosis of a previous LAD stent; (2) palliative MIDCAB, for multivessel disease with a significant underlying comorbidity such as severe left ventricular (LV) dysfunction (n=12, 18%), stroke (n=14, 21%), malignancy (n=4, 6%), and the expectation of a major operation (n=5, 7.5%); and (3) hybrid MIDCAB, in cases of multi-vessel disease where MIDCAB is performed simultaneously with a percutaneous coronary intervention (PCI) in another area (n=12, 18%). Hybrid MIDCAB was considered for patients with multi-vessel disease who had high-grade proximal disease of the LAD along with favorable lesions for PCI in the left circumflex (LCX) and right coronary artery (RCA) territories. There is no absolute contraindication for MIDCAB, but we generally did not perform MIDCAB in patients who were expected to have severe adhesions of the left hemithorax, poor pulmonary function, or an intra-myocardial course of the LAD based on preoperative computed tomography.

3) Technique
------------

We elevated the left hemithorax to 30°, attached external defibrillation pads, and prepared a double-lumen endotracheal tube. MIDCAB was performed through a 5- to 7-cm anterolateral minithoracotomy in the fourth or fifth intercostal space. Harvesting of the left internal mammary artery (LIMA) was done under direct visualization with a specially designed retractor while deflating the left lung, and we usually harvested the LITA in a skeletonized fashion as far as the proximal origin of the left subclavian artery. Heparin (1.5 mg/kg) was administered to maintain an activated clotting time over 300 seconds. A standard stabilizer for off-pump CABG (Octopus; Medtronic Inc., Minneapolis, MN, USA) was used. Under a beating heart, the anastomosis to the LAD was performed. The proximal LAD was snared with silastic loops. After the main procedure, we inserted a 24-Fr chest tube into the pleural space and the thoracotomy was closed in layers. If there was no evidence of bleeding, aspirin was started on the day of the operation.

4) Statistical analysis
-----------------------

For statistical analyses, we used IBM SPSS ver. 22.0 (IBM Corp., Armonk, NY, USA). Continuous variables are presented as mean±standard deviation or as median values with the range. Kaplan-Meier curves were used to analyze overall survival and freedom from MACCE.

Results
=======

We identified 66 consecutive MIDCAB patients with a mean age of 69.4±11.1 years, 73% of whom were male and 53% of whom had diabetes. The patients' preoperative characteristics are shown in [Table 1](#t1-kjtcv-51-008){ref-type="table"}. Their mean EuroSCORE II was 1.99±2.05 (range, 0.5 to 10.5). Twenty-six patients had normal LV function (ejection fraction \>60%), 28 patients had moderate LV dysfunction, and 12 patients had severe LV dysfunction (ejection fraction \<40%). Single- and multiple-vessel disease were present in 16 patients (24%) and 50 patients (76%), respectively. Twenty-six patients (39%) had a prior PCI, 3 patients (4.5%) had a prior CABG, and 1 patient (1.5%) had a prior aortic valve replacement. Thirteen patients (20%) had a history of an acute myocardial infarction.

The operative characteristics are shown in [Table 2](#t2-kjtcv-51-008){ref-type="table"}. The mean total operative time was 167 minutes (range, 75 to 405 minutes). There were no iatrogenic injuries to the LITA. Isolated LAD-only revascularization was performed in 58 patients (87.8%). A reconstructed composite graft with the saphenous vein was used for the anastomosis of additional branches or lengthening of the LITA graft in 8 patients. Twelve patients underwent a hybrid approach for suitable lesions of the LCX and/or RCA using a standard commercial stent immediately after surgery in the hybrid operating room or preoperatively. There were no conversions to an on-pump procedure, sternotomy, or intra-aortic balloon pump or extracorporeal membrane oxygenation support. Robot-assisted MIDCAB and combined operations required longer operative times. If we consider anterolateral minithoracotomy MIDCAB for isolated LAD revascularization (LITA to LAD), the actual mean operative time was 144 minutes.

The in-hospital outcomes are shown in [Table 3](#t3-kjtcv-51-008){ref-type="table"}. The 30-day mortality rate was 1.5% (1 of 66). One 81-year-old patient died due to idiopathic massive gastric bleeding on day 4 after surgery. There were no cerebrovascular events. Atrial fibrillation was observed in 5 patients (7.6%), but there were no cases of perioperative myocardial infarction or low cardiac output syndrome. Two patients (3.0%) had to be re-explored for bleeding. Two patients (3.0%) had a superficial wound problem associated with the thoracotomy. There was 1 case (1.5%) of pulmonary complication and 1 case (1.5%) of acute renal failure. Eighty-one percent of the patients were extubated in the operating room or on the day of surgery. The median stay in the intensive care unit and in the hospital were 23 hours (range, 13 to 526 hours) and 7 days (range, 4 to 57 days), respectively. Twenty patients (30.3%) received no transfusion.

The follow-up data are shown in [Table 4](#t4-kjtcv-51-008){ref-type="table"}. The median follow-up period was 11 months (range, 0 to 90 months). Except for in-hospital mortality, regular follow-up of the 65 survivors was completed in 100% of the patients, and their data were included in the outcome analysis. Among these patients, there were 7 late deaths (10.8%), among which 5 were due to cardiac causes (congestive heart failure). [Fig. 1](#f1-kjtcv-51-008){ref-type="fig"} shows the Kaplan-Meier survival curve of cumulative survival: the calculated 5-year overall survival rate was 85.3%±0.09%. One cerebrovascular event was observed. Two patients (3.1%) had a myocardial infarction due to an occluded LIMA graft and 1 patient was successfully treated with re-intervention on the target vessel. Another 3 patients (4.6%) had a re-intervention due to progressive disease of a non-target vessel during the follow-up period. [Fig. 2](#f2-kjtcv-51-008){ref-type="fig"} shows the calculated cumulative 5-year MACCE-free survival rate of 72.8%±0.1%. Forty-eight percent of the patients ( 32 of 66 ), with a total of 36 grafts, underwent a postoperative graft patency study with computed tomography angiography or coronary angiography. Eighty-nine percent of these grafts (32 of 36) were patent at 9.7±10.8 months postoperatively ([Table 5](#t5-kjtcv-51-008){ref-type="table"}).

Discussion
==========

In recent years, MIDCAB is increasingly becoming a potential alternative to conventional CABG, particularly among patients with high-grade proximal LAD stenosis that is unsuitable for PCI \[[@b8-kjtcv-51-008]\]. MIDCAB has several merits compared to off-pump CABG, including the fact that it is relatively safe and has a shorter recovery period. In addition, it is less likely to require transfusion or result in a wound infection, and it has a preferable course of postoperative physical recovery \[[@b9-kjtcv-51-008]\]. It has been confirmed that the early patency rates of MIDCAB patients are comparable to those of patients with anastomoses performed through bypass under cardioplegic arrest \[[@b3-kjtcv-51-008]\]. The anastomotic patency rate reported by Cremer et al. \[[@b10-kjtcv-51-008]\] was 98%. Furthermore, the overall patency rate of MIDCAB LAD grafting has been reported to be close to that of conventional grafting of the internal mammary artery to the LAD.

Controversy persists regarding whether MIDCAB or PCI is more suitable for isolated high-grade LAD stenosis patients. PCI has the advantages of not requiring general anesthesia, a large incision, or a long hospital stay \[[@b11-kjtcv-51-008]\]. However, MIDCAB has demonstrated more promising long-term angina-free and MACCE-free survival rates than PCI. Aziz et al. \[[@b12-kjtcv-51-008]\] reported a higher rate of recurrence of angina, incidence of MACCE, and need for repeat revascularization with PCI. In high-grade LAD stenosis patients, CABG showed better outcomes than PCI in terms of MACCE-free survival at a 3-year follow-up in a single-center prospective trial \[[@b13-kjtcv-51-008]\]. In 5 years of follow-up in the SYNTAX trial, PCI had a significantly higher incidence of MACCE (46.5% versus 29.0%, p\< 0.0001) and repeat revascularization (35.3% versus 14.6%, p\<0.0001) than CABG \[[@b14-kjtcv-51-008]\]. Although the recent European Society of Cardiology/European Association for Cardio-Thoracic Surgery guidelines on myocardial revascularization revised the indications for the treatment of coronary artery disease, CABG still should be recommended as a primary treatment as a class I indication with a level of evidence of A or B except for 1- or 2-vessel disease without proximal LAD stenosis \[[@b15-kjtcv-51-008]\].

Our in-hospital outcomes are comparable to those of other studies. The mortality rate was 1.5% in our study, due to a single case of massive gastric bleeding. None of our patients had a stroke. The conversion rate from minithoracotomy to sternotomy with cardiopulmonary bypass in our experience was 0%. Two patients (3.0%) had to be re-explored for bleeding; one was bleeding from an intercostal vessel and the other was a hematoma of unknown origin. Our wound problem rate was 3.0%, which was accounted for by cases of superficial wound dehiscence. The ventilation time was very short (median, 4 hours), and 81.8% of our patients were extubated in the operating room or on the day of surgery. However, we did not show a significantly reduced hospital stay (median, 7 days) or transfusion rate (70%). Our indications for MIDCAB included palliative therapy for conditions such as multi-vessel disease with heart failure (n=12, 18%), a preoperative bed-ridden state with stroke (n=14, 21%), and acute coronary syndrome (n=42, 64%), resulting in longer hospital stays and a need for more transfusions. Our follow-up data showed a 5-year overall survival rate of 85.3%±0.09% and a 5-year MACCE-free survival rate of 72.8%±0.1%, which are acceptable compared with other studies.

Twelve patients (18%) were hybrid cases that underwent the stenting of suitable non-LAD vessels during the same admission by cardiologists. PCI on the culprit lesion prior to MIDCAB was performed for 6 acute coronary syndrome patients; MIDCAB and PCI were simultaneously performed in 5 patients in the hybrid operating room, and 1 patient underwent additional planned PCI on postoperative day 1. These patients showed better outcomes than the other patients, with no early or late mortality and no MACCE. Complete revascularization through a hybrid approach seems to have been important for the late outcomes of these patients, although this issue must be investigated in a larger study. As we found good clinical outcomes, the hybrid procedure may evolve to become a useful option for multi-vessel disease in high-risk patients \[[@b16-kjtcv-51-008]\].

Thirty-two of the 66 patients who had atypical chest pain or agreed to have their grafts evaluated underwent a postoperative graft patency study with computed tomography angiography or coronary angiography. We found that 88.9% of the grafts (32 of 36) were patent at 9.7±10.8 months postoperatively. Isolated LITA-to-LAD grafts were more likely to be patent (26 of 28, 93%) than saphenous vein grafts (4 of 6, 67%) or other grafts (5 of 7, 71%) in our data. Our patency rate is slightly lower than that of other studies because we only investigated less than half of the population (48.5%) who complained of atypical chest pain, and there was a liberal use of saphenous vein grafts and non-LAD territory anastomoses.

Our results showed a favorable graft patency rate of LIMA-to-LAD anastomoses after MIDCAB. Our early re-intervention rate for anastomosis stenosis was 1.5%, whereas Holzhey et al. \[[@b16-kjtcv-51-008]\] reported a rate of 3.3%. The low rate of re-intervention was an indicator of graft patency. Although the postoperative follow-up period in our patients was short, the high graft patency rate after MIDCAB may indicate that MIDCAB had substantial benefits in high-risk patients, even among those with multi-vessel disease \[[@b17-kjtcv-51-008]\]. This may reflect the safety of MIDCAB, making it a good surgical option for the treatment of coronary artery disease \[[@b18-kjtcv-51-008]\].

Based on our findings, we suggest that MIDCAB is a feasible method with acceptable outcomes, including a low rate of stroke, postoperative mortality, morbidity, infections, and transfusions; short intensive care unit and hospital stays; and good graft patency. The good clinical outcomes including excellent survival and a low rate of recurrent angina, myocardial infarction, and re-intervention rates were made possible by the excellent patency of the LIMA-LAD grafts \[[@b11-kjtcv-51-008]\].

1) Limitations
--------------

This was a study of relatively few patients, and it was an uncontrolled, nonrandomized, single-center, retrospective study. The postoperative follow-up period in our patients was short. Although 100% of patients were followed up, computed tomography angiography or coronary angiography was not performed to evaluate graft patency in all patients. Additionally, a clinical trial comparing conventional bypass and PCI to MIDCAB has not been conducted.

2) Conclusion
-------------

In summary, MIDCAB is a safe and beneficial procedure with low postoperative morbidity, mortality, and acceptable 5-year MACCE-free survival and freedom from re-intervention in selected patients. The results of our study suggest that MIDCAB is a safe and effective therapy capable of achieving effective mid-term revascularization and acceptable clinical outcomes.
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###### 

Preoperative data of 66 patients

  Characteristic                                                         Value
  ---------------------------------------------------------------------- ------------------------------
  Age (yr)                                                               69.4±11.1
  Male sex                                                               50 (73)
  Hypertension                                                           45 (68)
  Dyslipidemia                                                           21 (32)
  Diabetes mellitus                                                      35 (53)
  Chronic renal failure                                                  11 (17)
  Chronic obstructive pulmonary disease                                  4 (6)
  Cerebrovascular accident                                               14 (21)
  Smoking                                                                35 (53)
  Malignancy                                                             4 (6)
  EuroSCORE II (%)                                                       1.99±2.05 (range, 0.5--10.5)
  Mean EF                                                                53.7
  Left ventricular dysfunction (EF \<40%)                                12 (18)
  3VD                                                                    27 (41)
  2VD                                                                    23 (35)
  1VD                                                                    16 (24)
  Previous percutaneous coronary intervention                            26 (39)
  Peripheral arterial occlusive disease                                  6 (9)
  Redo open heart surgery[a)](#tfn3-kjtcv-51-008){ref-type="table-fn"}   4 (6)
  Silent/stable angina                                                   24 (37)
  Unstable angina                                                        29 (44)
  STEMI/non-STEMI                                                        13 (20)

Values are presented as mean±standard deviation or number of patients (%).

EF, ejection fraction; VD, vessel disease; STEMI, ST-segment elevation myocardial infarction.

Coronary artery bypass graft surgery (n=3) and aortic valve replacement (n=1).

###### 

Operative characteristics

  Characteristic                                                    Value
  ----------------------------------------------------------------- -------------------------
  Length of operation (min)                                         167±55 (range, 75--405)
  Distal anastomosis                                                1.15±0.44
   1                                                                58 (87.8)
   2                                                                7 (10.7)
   3                                                                1 (1.5)
  Hybrid approach                                                   12 (18)
  Incomplete revascularization                                      17 (26)
  Conversion to sternotomy                                          0
  IABP/ECMO support[a)](#tfn5-kjtcv-51-008){ref-type="table-fn"}    0
  Video-assisted thoracoscopic surgery/robot-assisted               3 (5)
  Combined operation[b)](#tfn6-kjtcv-51-008){ref-type="table-fn"}   3 (5)

Values are presented as mean±standard deviation or number of patients (%).

Intra-aortic balloon pump support and extracorporeal membrane oxygenation support.

Abdominal aortic aneurysm (n=2) and lung cancer (n=1).

###### 

In-hospital outcomes

  In-hospital outcome                                                Value
  ------------------------------------------------------------------ ---------------------
  Mortality (30-day)                                                 1 (1.5)
  Morbidity                                                          
   Stroke                                                            0
   Atrial fibrillation                                               5 (7.6)
   Perioperative myocardial infarction/low cardiac output syndrome   0
   Bleeding reoperation                                              2 (3.0)
   Wound problems                                                    2 (3.0)
   Pulmonary complication                                            1 (1.5)
   Acute renal failure                                               1 (1.5)
  Transfusion, packs of red blood cells                              46 (69.7)
  Ventilator (hr)                                                    12.0±41.8 (1--336)
  Intensive care unit stay (hr)                                      38.2±69.3 (13--526)
  Hospital stay (day)                                                9.6±8.7 (4--57)

Values are presented as number of patients (%) or mean±standard deviation (range).

###### 

Follow-up data of 65 patients

  Follow-up data                        No. of patients (%)
  ------------------------------------- ---------------------
  Mortality                             7 (10.8)
   Cardiac                              5 (7.7)
   Non-cardiac                          2 (3.1)
  Morbidity                             
   Stroke                               1 (1.5)
   Myocardial infarction                2 (3.1)
  Target vessel revascularization       1 (1.5)
  Non-target vessel revascularization   3 (4.6)

###### 

Results of postoperative computed tomography angiography or coronary angiography in 32 patients with a total of 36 grafts

                                 Left anterior descending artery   Left circumflex artery   Right coronary artery   Total
  ------------------------------ --------------------------------- ------------------------ ----------------------- ------------
  Left internal mammary artery   26/28 (93)                        \-                       \-                      26/28 (93)
  Saphenous vein graft           \-                                4/5 (80)                 0/1 (0)                 4/6 (67)
  Radial artery                  1/1 (100)                         1/1 (100)                \-                      2/2 (100)
  Total                          27/29 (93)                        5/6 (83)                 0/1 (0)                 32/36 (89)

Values are presented as number of patent grafts/number of total grafts (%).
